Allogene Therapeutics, Inc. announced the company’s Board of Directors. The Allogene Board of Directors: Arie Belldegrun, M.D., FACS – Executive Chairman and Co-Founder of Allogene; David Bonderman – Chairman and Founding Partner of TPG; David Chang, M.D., Ph.D. – President, Chief Executive Officer and Co-Founder of Allogene; Franz B. Humer, Ph.D. – Former Chairman and Chief Executive Officer of Roche Holding Ltd.; John DeYoung – Vice President, Worldwide Business Development at Pfizer; Joshua Kazam – Co-Founder and Partner of Two River and Co-Founder of Allogene; Owen Witte, M.D. – University Professor of Microbiology, Immunology and Molecular Genetics at the UCLA, David Saxon Presidential Chair in Developmental Immunology; and Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA; Robert Abraham, Ph.D. - Senior Vice President and Group Head, Oncology R&D Group at Pfizer; Todd Sisitsky – Managing Partner of TPG Capital.